DNLI
Price
$12.74
Change
+$0.19 (+1.51%)
Updated
Apr 17 closing price
Capitalization
1.85B
24 days until earnings call
IMVT
Price
$15.15
Change
+$0.31 (+2.09%)
Updated
Apr 17 closing price
Capitalization
2.57B
39 days until earnings call
Ad is loading...

DNLI vs IMVT

Header iconDNLI vs IMVT Comparison
Open Charts DNLI vs IMVTBanner chart's image
Denali Therapeutics
Price$12.74
Change+$0.19 (+1.51%)
Volume$979.18K
Capitalization1.85B
Immunovant
Price$15.15
Change+$0.31 (+2.09%)
Volume$1.04M
Capitalization2.57B
DNLI vs IMVT Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. IMVT commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and IMVT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (DNLI: $12.74 vs. IMVT: $15.15)
Brand notoriety: DNLI and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 71% vs. IMVT: 58%
Market capitalization -- DNLI: $1.85B vs. IMVT: $2.57B
DNLI [@Biotechnology] is valued at $1.85B. IMVT’s [@Biotechnology] market capitalization is $2.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, IMVT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while IMVT’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • IMVT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both DNLI and IMVT are a good buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +1.92% price change this week, while IMVT (@Biotechnology) price change was +2.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

IMVT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.57B) has a higher market cap than DNLI($1.85B). DNLI (-37.488) and IMVT (-38.837) have similar YTD gains . IMVT has higher annual earnings (EBITDA): -404.87M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. IMVT (375M). IMVT has less debt than DNLI: IMVT (23K) vs DNLI (48.7M). DNLI (0) and IMVT (0) have equivalent revenues.
DNLIIMVTDNLI / IMVT
Capitalization1.85B2.57B72%
EBITDA-492.89M-404.87M122%
Gain YTD-37.488-38.83797%
P/E RatioN/AN/A-
Revenue00-
Total Cash832M375M222%
Total Debt48.7M23K211,739%
FUNDAMENTALS RATINGS
DNLI vs IMVT: Fundamental Ratings
DNLI
IMVT
OUTLOOK RATING
1..100
5872
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8891
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (63) in the null industry is in the same range as DNLI (94) in the Biotechnology industry. This means that IMVT’s stock grew similarly to DNLI’s over the last 12 months.

IMVT's Profit vs Risk Rating (86) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that DNLI’s stock grew similarly to IMVT’s over the last 12 months.

DNLI's Price Growth Rating (88) in the Biotechnology industry is in the same range as IMVT (91) in the null industry. This means that DNLI’s stock grew similarly to IMVT’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that DNLI’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIIMVT
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X84895.750000861.882800
+1.03%
Bitcoin cryptocurrency
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with ARWR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.51%
ARWR - DNLI
58%
Loosely correlated
-0.97%
BEAM - DNLI
58%
Loosely correlated
+2.29%
RCKT - DNLI
58%
Loosely correlated
+2.93%
NTLA - DNLI
56%
Loosely correlated
+5.39%
RGNX - DNLI
55%
Loosely correlated
-3.57%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+2.09%
ROIV - IMVT
60%
Loosely correlated
+1.30%
RCKT - IMVT
50%
Loosely correlated
+2.93%
DNLI - IMVT
47%
Loosely correlated
+1.51%
XENE - IMVT
45%
Loosely correlated
+3.94%
IDYA - IMVT
45%
Loosely correlated
+5.56%
More